Semaglutide API Peptide Raw Powder Synthesis CAS 910463-68-2

  • Description
  • Inquiry


Semaglutide is a glucagon-like peptide-1 (GLP-1) analog and functions as a GLP-1 agonist. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use
  • Semaglutide is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans.
  • Semaglutide has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
  • Semaglutide is not a substitute for insulin. Semaglutide is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.


Product NameSemaglutide
Cas No. 910463-68-2
Molecular FormulaC187H291N45O59
Molar Mass 4,113.64 g·mol
Impurity ≤0.5%
Storage Temperature 2-8ºC
Packing Sizemin.1G, vial or aluminum foil bag.